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Abstract
Introduction and hypothesis The purpose of this study is to
compare retropubic tension-free vaginal tape (TVT) with
transobturator out-in TOT and in-out TVT-O for female
stress urinary incontinence. Uroflow rate was primary;
continence rates, quality of life (QoL) and complication
pattern were secondary endpoints.
Methods A prospective randomised trial with 2:1:1 ran-
domisation at two Swiss teaching hospitals. Patients were
followed up at 12 months.
Results Eighty TVT, 40 transobturator tape (TOT) and
40 TVT-O were randomised. At 12 months, there was
no difference in Qmax among the groups. Continence
was comparable (≥89%). QoL was improved signifi-
cantly in all groups (P<0.05). Five vaginal tape expo-
sures occurred (one TVT, four TOT, zero TVT-O;
P=0.028). Two percent (1/52) of sexually active patients
after TVT, 17% (5/29) after TOT, but 0% (0/25) after TVT-
O reported de novo female sexual dysfunction (P=0.011).
We considered this clinically important enough to stop
enrolment.
Conclusions There was no difference for Qmax at
12 months between TVT, TOT and TVT-O. Female sexual
dysfunction and tape exposure may be higher with a
transobturator tape.
Keywords Tension-free vaginal tape . Transobturator tape .
TVT. TOT. TVT-O . Stress urinary incontinence (SUI)
Introduction
The concept of the retropubic tension-free vaginal tape (TVT)
facilitated surgery for female stress urinary incontinence (SUI)
[1]. An 11-year follow-up showed the effectiveness of the
TVT operation with a long-term objective cure rate of 90%
[2]. However, the retropubic trocar passage is associated with
intraoperative complications, including bladder perforation,
major blood vessel injuries and postoperative voiding
difficulties [3–6]. These concerns resulted in the introduction
of the transobturator (TO) technique in 2001. The TO tape is
inserted tension-free from the thigh folds (outside-in) in a
horizontal plane underneath the midurethra between the two
obturator foramina [7]. It was hypothesised that the horizontal
course would cause less obstruction. To minimise bladder and
urethra perforation, an inside-out modification was developed
by passing the tape from underneath the urethra (inside)
through the obturator foramina towards the thigh folds
(outside) under guidance of a protecting introducer [8].
We introduced the TVT operation in 1999 and the TO
technique in 2003. Until 2005, no randomised trial
compared these three procedures while few trials showed
comparable postoperative continence rates for TVT and TO
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tapes. Only recently, an equivalence trial has been designed
to determine if efficacy rates were the same [9]. So far,
there is no longer-term comparative data of efficacy
between retropubic and transobturator tapes. The impor-
tance of looking at any issue with any midurethral sling is
for patient safety and efficacy. We started the present study
to address this. We opted for uroflow rates as primary
outcome as reduction in urinary flow rate was shown after
midurethral sling insertion [10, 11]. Primary endpoint was
micturition (urinary flow); secondary endpoints were
continence, quality of life (QoL) and complications at
12 months.
Materials and methods
Two public teaching hospitals in Switzerland, the University
Hospital Zurich and the Cantonal Hospital Uri, participated in
this study. Women with urodynamically confirmed SUI or
mixed urinary incontinence with predominant component of
SUI who were referred for incontinence surgery between
January 2006 and October 2009 were invited to participate.
After written informed consent, they were randomised for one
of the following three tapes: the TVT (Gynecare, Johnson &
Johnson, NJ, USA), the outside-in transobturator sling
Monarc (American Medical Systems, Minnetonka, USA)
and the inside-out TVT-O (Gynecare, Johnson & Johnson, NJ,
USA), in a relation of 2:1:1, using predetermined computer-
generated block randomisation in blocks of eight to promote
group balance. Exclusion criteria were missing urodynamic
assessment, previous sling procedure, predominant overactive
bladder syndrome (OAB), a post-void residual urine volume
(PVR) above 100 ml, pregnancy or considering further
pregnancy, known or suspected coagulopathy and known
allergy to local anaesthetics. Patients unable to understand
German, or unavailable or unwilling for follow-up were
excluded as well. Preoperatively, conservative measures for
SUI were recommended, such as use of local estrogens, pelvic
floor reeducation, or incontinence pessaries. A symptomatic
cystocele stage 2 or higher according to the POP-Q system
was corrected first. Patients with concomitant sling insertion
to prolapse repair were eligible as well.
Experienced gynaecologists performed the procedures
according to the original methods, preferably under
analgesia and sedation. In addition, the first ten procedures
were supervised by a urogynaecologist. There was no
randomisation between operators and additional proce-
dures. Cefazolin or—in case of penicillin allergy—clinda-
mycin was given as prophylactic single-shot antibiotic.
Cystoscopy was mandatory for every procedure. To
determine appropriate tape tension, a cough test was
performed, and Metzenbaum scissors were placed as spacer
between tape and urethra to ascertain a tension-free
position. An indwelling catheter was placed in case of
concomitant prolapse surgery, intraoperative bladder injury
or increased intraoperative bleeding with need of intra-
vaginal packing.
Urogynaecologic assessment included preoperative col-
lection of medical history, PVR by catheterisation, clinical
examination and urodynamic study with cystometry and
urethral pressure profilometry, perineal sonography, cough
and short-pad test and free-flow uroflowmetry to assess
maximum urinary free-flow rate (Qmax). Quality of life
(QoL) was assessed by means of the validated German
version of the King’s Health Questionnaire (KHQ) [12].
The KHQ consists of 32 items that address ten domains of
QoL. Each domain is scored using a range between 0 and
100, while higher scores indicate greater impairment of
QoL. In addition, a visual analog scale (VAS), where 0
represents no urinary complaints and 10 unbearable urinary
complaints, was used to assess symptom bother at baseline
and at follow-up [13].
Data collection included perioperative characteristics and
complications. A first postoperative follow-up was per-
formed at 2 weeks for clinical examination and assessment
of PVR. Follow-up at 6 weeks, 6 and 12 months included
medical history, re-assessment of QoL, clinical examina-
tion, PVR by catheterisation, perineal sonography, cough
and short-pad test and free-flow uroflowmetry. Urodynamic
studies were performed in supine position, using "Androm-
eda Ellipse" with three-lumen water-filled 9-French cathe-
ters, as well as perineal sonography (Kretz Voluson 530 D
and Voluson 730 Pro with 3D abdominal probe) at a bladder
filling of about 300 ml of physiological saline solution,
using a midsagittal view [14]. We assessed tape position as
the mid-point of the sling in relation to the urethral length,
where 0% represents the internal and 100% the external
meatus urethrae [15]. The physicians carrying out the
follow-up were not blinded.
Objective continence was defined as both a negative
cough and a negative short-pad test, performed with a
bladder filling of 300 ml. The cough test is performed in
supine position and defined negative as no involuntary
leakage occurs synchronously with coughing. Our short-
pad test is suitable for lesser agile patients and consists of
ten times coughing, ten times climbing up and down a
small base and ten times coughing while squatting. A pad
weight gain less than 3 g is defined as negative. Subjective
continence was assessed by means of patient’s global
impression (cured, improved, failed). Normal postoperative
voiding was achieved as soon as PVR was below 100 ml
within the first week. Tape loosening or division by
complete incision was discussed in case of persisting
symptomatic PVR with voiding difficulties (e.g. straining),
requiring intermittent clean self-catheterisation, de novo
urge or recurrent urinary tract infection. After having
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noticed the occurrence of postoperative sexual dysfunction,
we subsumed disorders associated with sexual intercourse
under the term "female sexual dysfunction" (FSD) while
excluding partner dyspareunia, (hispareunia) caused by
vaginal tape exposure, as a separate entity [16, 17].
Based on published data at study initiation, we assumed
equivalence for all techniques in regard to efficacy and
continence but fewer obstruction in the TO group.
Therefore, we used Qmax at 12 months as primary
endpoint. We hypothesised a postoperative Qmax of 26
and 30 ml/s (SD±10) in the TVT and TO group,
respectively. Based on 0.8 power to detect this difference,
a total of 200 patients was estimated (P=0.05, two-sided).
Secondary outcome measures included objective and
subjective continence, QoL, PVR, tape position, urinary
retention, tape loosening or division and tape exposure.
Data entry and management were carried out using
FileMaker Pro 9.0 (FileMaker, Inc., CA) and the clinical
information system KISIM (Cistec AG, Zurich, Switzerland).
The data were treated anonymously. Statistic evaluation
was undertaken using Intercooled Stata 8.2 (StataCorp
LP, College Station, TX) by means of the non-
parametric Kruskal–Wallis test for continuous and count
data and Fisher’s exact test for categorical data, as
appropriate. Patients with and without obstructive
symptoms within treatment groups were compared using
the Mann–Whitney U test. Changes within treatment
groups were analysed using Wilcoxon signed rank test. P
values below 0.05 indicate statistical significance (two-
sided). Analysis is undertaken following the intention-to-
treat principle by analysing the groups according to their
randomisation. Our study followed the guidelines for good
urodynamic practice for the measurement and, where
possible, the Consolidated Standards of Reporting Trials
(CONSORT) guidelines for randomised clinical trials.
Ethical approval was obtained from the local Cantonal
ethics committees of Zürich (ref StV 20/2005, December
2005) and Altdorf (Amt für Gesundheit, 24.2.2006), with
obligation of yearly interim reports. After the mandatory
interim analysis revealed an unanticipated high rate of
FSD for transobturator tape (TOT), we stopped further
enrolment. This study is registered with ClinicalTrials.gov,
number NCT00642109.
Results
Between January 2006 and October 2009, 243 women met
the study inclusion criteria (Fig. 1). Eighty-three patients
were excluded from enrolment—44 preferred the TVT as
established method; three lived too far away for follow-up,
and, in 36 cases, we followed the preference of the referring
gynaecologist. Therefore, 160 were included—150 at the
University Hospital Zurich and ten between February 2006
and December 2007 at the Cantonal Hospital Uri. Twelve-
month follow-up data was not available in 24 patients due
to patient withdrawal, tape release, second tape insertion at
6 months or intravesical Botox injection for persistent
refractory OAB at 10 months (P=0.72). The last 12-month
follow-up was in October, 2010.
Preoperative baseline data are listed in Table 1. The three
groups showed comparable baseline characteristics. The
trial was stopped early due to an unexpected occurrence of
de novo FSD in TOT.
Perioperative characteristics including operative details
and hospitalisation time are presented in Table 2. No
statistically significant differences were found between the
three groups. Nine surgeons performed the sling proce-
dures with similar distribution of the performed proce-
dures. One TVT did not receive allocated surgery
because of intraoperative conversion to TOT after futile
attempts to place the trocar correctly, repeatedly ending
in bladder perforation.
Outcome and findings of the 136 eligible patients at the
12-month follow-up are summarised in Table 3. Qmax was
decreased significantly by TVT, TOT and TVT-O (P<.001,
P=.050, P=.010, respectively; Tables 1 and 3). The mean
difference of Qmax at 12 months between the retropubic
TVT and the transobturator slings (TOT and TVT-O
together) was 1.6 ml/s with a 95% confidence interval
from −1.5 to 4.6 ml/s. So we cannot exclude a moderate
difference of 4.6 ml/s between retropubic and transobturator
slings. No statistically significant difference was found
postoperatively between the groups for Qmax (P=0.26),
PVR (P=0.66), or obstructive voiding symptoms like
straining or slow stream (P=0.71). Compared with patients
reporting normal voiding, obstructive symptoms were
associated with lower Qmax (TVT 21.5±7.6 vs. 12.6±
8.0 ml/s, P=0.007; TOT 24.4±8.6 vs. 11.0±3.5 ml/s, P=
0.050; TVT-O 21.6±6.3 vs. 14.1±7.3 ml/s, P=0.07) but not
with elevated PVR.
Objective continence was comparable for all three
groups (TVT 94%, TOT 91% and TVT-O 89%; P=0.72).
Assuming incontinence for all excluded patients, conti-
nence would have been achieved in 73%, 78% and 83%,
respectively (P=0.48). Assuming continence, a comparable
rate for the three groups would be found as well (95%,
93%, 90%, respectively; P=0.60). All sling types improved
quality of life (P<0.05), assessed by KHQ and VAS
(Table 4).
After excluding nine women with concomitant prolapse
surgery, no statistically significant differences were found
either for objective continence (P=0.79) or subjective
success by means of patients global impression (P=0.79);
also, Qmax, PVR or midtape position at 12 months were
comparable (P=0.34, P=0.90, P=52, respectively).
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Table 1 Patient characteristics (N=160)
N TVT TOT TVT-O
N randomised 160 80 40 40
Age, years 160 57.8±13.0 (33.9–85.4) 56.6±10.3 (40.5–84.8) 59.3±12.1 (33.9–81.8)
BMI, kg/m2 160 26.4±3.7 (18.9–35.9) 27.8±4.6 (18.7–41.5) 27.6±4.8 (19.2–39.2)
Parity 160 2.0±1.0 (0–4) 2.6±1.5 (0–8) 2.3±1.1 (0–5)
MUCP, cmH2O 160 49.9±26.4 (2–121.8) 48.4±25.0 (14–114.2) 51.4±25.0 (13.7–104.8)
Qmax, ml/s 146 28.9±12.1 (9.6–64.6) 29.9±11.7 (13.1–58.5) 27.0±13.7 (8–69.8)
PVR (ml) 156 18.9±19.6 (0–95) 15.0±18.4 (0–60) 13.2±14.9 (0–50)
OAB dry 160 25 (31.3%) 9 (22.5%) 13 (32.5%)
OAB wet 8 (10.0%) 2 (5.0%) 3 (7.5%)
S/p hysterectomy 160 24 (30.0%) 14 (35.0%) 10 (25.0%)
S/p colporrhaphia anterior 160 5 (6.3%) 4 (10.0%) 7 (17.5%)
S/p colporrhaphia posterior 160 5 (6.3%) 3 (7.5%) 4 (10.0%)
Data are expressed as mean±standard deviation and range (minimum—maximum), or number of patients (percent)
TVT tension-free vaginal tape, TOT outside-in transobturator tape Monarc, TVT-O inside-out transobturator tape TVT-O, BMI body mass index,
MUCP maximum urethral closure pressure, Qmax maximum urinary free flow (Uroflow), PVR post-void residual urine volume, OAB overactive
bladder syndrome
MUCP: excludes missing values (n=1 in the TVT group)
PVR: excludes missing values (n=2 in the TVT group, n=1 in the TOT group, n=1 in the TVT-O group)
TVT retropubic
Allocated to TVT (n = 80)
Received allocated TVT (n = 79)
Received TOT (n = 1):
Conversion due to bladder perforation
TVT-O inside-out
Allocated to TVT-O (n = 40)
Received allocated TVT-O (n = 40)
TOT outside-in
Allocated to TOT (n = 40)
Received allocated TOT (n = 40)
Followed up at 12 months (n = 65)
Lost to follow up (n=15):
Tape release (n=3)
1 at 2 months (urinary retention)
1 at 4 months (vaginal tape exposure)
1 at 6 months (de-novo urge)
TOT insertion at 6 months (n=1)
BTX (known OAB) at 10 months (n=1)
Patient's withdrewal (n=10)
Followed up at 12 months (n = 34)
Lost to follow up (n=6):
Patient's withdrawal (n=6)
Followed up at 12 months (n = 37)
Lost to follow up (n=3):
Tape release* at 2 months (urinary retention) (n=1)
Patient's withdrewal (n=2)
1 recently diagnosed breast cancer at 5 months
Eligible to analysis (n=65)
Not eligible for the 12-months follow up (n=15):
Tape release (n=3)
TOT insertion (n=1)
BTX (n=1)
Patients withdrew (n=10)
Randomisation
2 TVT : 1 TOT : 1 TVT-O
in blocks of eight
Tape release due to vaginal tape exposure (n=2):
At 14 months with TVT insertion
At 18 months
BTX (persisting OAB) at 30 months (n=1)
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Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow
chart of enrolment and follow-up showing progress of patients
through trial. TVT tension-free vaginal tape, TOT outside-in trans-
obturator tape Monarc, TVT-O inside-out transobturator tape, OAB
overactive bladder syndrome, BTX intravesical injection of Botox
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Of the 124 slings inserted under local anaesthesia, a
postoperative PVR below 100 ml was achieved on day of
operation in 23 TVT (40%), 21 TOT (37%) and 13 TVT-O
(23%), the next day in 31 TVT (58%), 11 TOT (20%) and
12 TVT-O (22%), and on day 2 or later, in six TVT (50%),
four TOT (33%) and two TVT-O (17%) (P=0.34).
Table 5 shows the tape-related complication pattern
including all events up to 12 months postoperatively.
Work-up of one patient in the TVT-O group with intra-
operative blood loss of 500 ml revealed von Willebrand
disease. In one TVT, haemorrhage in the retropubic space
required laparotomy the next day. Because this patient
remained incontinent, she received a TOT at 6 months and
was cured then. Urinary retention necessitated tape release
by complete midline incision in one TVT after 2 months as
well as in one TVT-O after 2 months. One TVT was
released after 6 months due to persisting de novo urge.
Vaginal tape exposure within 12 months occurred more
often in the TOT group (one TVT, four TOT, zero TVT-O)
(P=.028) and required after 4 months partial excision of the
TVT, after 14 months of one TOT and after 18 months in
another TOT causing hispareunia. Twelve patients (7%)
reported sexual dysfunction—two TVT, six TOT and four
TVT-O. None of these 12 patients had concomitant prolapse
surgery, but two patients with TOT and two with TVT-O had
combined colporrhaphia anterior and posterior at a separate
event prior to sling insertion. After excluding one TVT and
one TOT with vaginal tape exposure as cause for hispar-
eunia, and four patients with TVT-O reporting persisting
preoperative FSD, de novo FSD occurred in one out of 52
sexually active patients with TVT and in five out of 29 with
TOT, but in 0 out of 25 TVT-O (P=0.011; Table 5).
Complaints included de novo dyspareunia in one TVT and
two TOT, a feeling of vaginal narrowing in two TOT, and
neuralgiform pain at the ischiocrural tape exit point in one
TOT. In two patients with TOT, de novo FSD subsided after
12 months. The other four patients preferred an expectant
procedure. No association between tape exposure or FSD
and surgeon was found.
We considered the unexpected occurrence of de novo
FSD in TOT in our trial clinically important enough to stop
enrolment. Generating one million datasets with two
cumulative interim analysis in order to correct the P value
for “picking extreme values” revealed a corrected P value
of P=0.016. Further enroling without informing about the
possible occurrence of FSD was not regarded as ethical.
Table 2 Perioperative details (n=160)
TVT TOT TVT-O P value
N randomised 80a 40 a 40 –
Local anesthesia (time for application) (min)d 6.4±1.8 (3–10) 5.7±1.6 (3–10) 6.0±1.8 (5–12) 0.19b
Operation time (from incision to closure) (min)d 26.7±11.5 (15–100 a) 25.8±9.7 (15–50) 27.4±10.0 (15–54) 0.68b
Blood loss (ml)d 34.4±36.5 (5–250) 31.5±22.2 (10–100) 49.4±89.6 (10–500) 0.96b
Type of anesthesia 0.088c
Local 60 (75.0%) 36 (90.0%) 28 (70.0%)
Regional 8 (10.0%) 1 (2.5%) 8 (20.0%)
General 12 (15.0%) 3 (7.5%) 4 (10.0%)
Concomitant surgery 7 (8.8%) 2 (5.0%) 4 (10.0%) 0.81c
Concomitant POP surgery 6 (7.5%) 0 (0%) 3 (7.5%) 0.25c
Hysterectomy 3 (3.8%) 2 (5.0%) 4 (10.0%) 0.44c
Colporrhaphia anterior 3 (3.8%) 0 (0%) 3 (7.5%) 0.22c
Colporrhaphia posterior 6 (7.5%) 0 (0%) 2 (5.0%) 0.23c
Sacrospinal ligament fixation 2 (2.5%) 0 (0%) 0 (0%) 0.50c
Other procedure(s) 11 (13.8%) 3 (7.5%) 4 (10.0%) 0.65c
Hospitalisation (days)d 3.5±1.1 (3–10e) 3.2±0.5 (3–5) 3.3±0.8 (3–6) 0.14b
Data are expressed as mean±standard deviation and range (minimum–maximum), or number of patients (percent)
TVT tension-free vaginal tape, TOT outside-in transobturator tape Monarc, TVT-O inside-out transobturator tape TVT-O, POP pelvic organ
prolapse
a One conversion from TVT to TOT due to bladder perforation, resulting in 79 inserted TVT, 41 TOT and 40 TVT-O
bKruskal–Wallis test
c Fisher‘s exact test
d Sling insertion without concomitant procedure (n=131)
e One TVT required laparotomy for haemorrhage into the retropubic space, resulting in a hospitalisation duration of 10 days
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Discussion
Based on anatomical and theoretical considerations, the
rational for the TO techniques was to reduce bladder, bowel
and major blood vessel injuries as caused by the retropubic
route, but not superiority over TVT [18]. When TO slings
started to spread increasingly, few randomised trials com-
pared the techniques at that time. The importance of looking
at any issue with any midurethral sling is for patient safety
and efficacy. Thus, we initiated this trial to compare the three
commonly used midurethral slings in Switzerland.
Authors increasingly discuss complication issues in
recent literature [3, 9, 19]. But, to compare complications
meaningfully, meta-analysis, multi-centre or national regis-
tries are preferable [20]. In contrast, voiding dysfunction
after incontinence procedures are common [21]. We
calculated the sample size based on Qmax. In our trial,
voiding dysfunction occurred comparably in the three
groups. In this respect, no group was advantageous.
Obstruction was easily resolved within the first postopera-
tive days by tape loosening [22]. However, because the trial
was stopped sooner, it is under-powered to detect a
difference in Qmax as primary outcome.
Our trial showed comparably good continence as well as
improved QoL after 12 months for the three groups. We
were aware that a higher number of subjects would be
needed in order to detect statistically significant differences
in continence. Several meta-analysis, systematic reviews
and recent large multicentre comparative-effectiveness trial
could not reveal clear superiority of one technique [3–6, 9].
A recent meta-analysis showed evidence for equivalent
effectiveness of TOT and TVT-O [23]. In the long-term,
recurrent incontinence could be higher after TOT [24].
An unexpected complication pattern led us to stop
enrolment prematurely: de novo female sexual dysfunction.
We noted a higher perioperative complication rate in the
TVT group, such as bladder perforation, quickly solved by
replacing the trocar. In contrast, we found more mid-term
complications in the TOT group, such as vaginal tape
exposure, FSD or hispareunia. For future reporting of these
complications, the recently published consensus-based
terminology and classification report for prostheses and
grafts complications in female pelvic floor surgery will be
helpful in clinical practice and research [25]. One possible
explanation for the higher incidence of tape exposure in TO
tapes is their close passage next to the vaginal sulci. In
women with high lateral sulci, vaginal tape exposure could
occur more frequently. Here, a procedure under protected
guidance of an introducer could be favourable by avoiding
a too-close passage to the vaginal wall. Then again,
Table 3 Twelve-month assessment (n=136)
N TVT TOT TVT-O P value
136 65 34 37 –
12-month follow-up, months 12.4±0.8 (11.7–16.0) 12.8±1.6 (10.8–18.3) 12.5±1.3 (9.9–18.2) 0.75a
Objective continence 133 0.72b
Yes (both negative cough and negative short-pad test) 58 (93.6%) 31 (91.2%) 33 (89.2%)
No (positive cough or positive short-pad test) 4 (6.4%) 3 (8.8%) 4 (10.8%)
Subjective success (patient’s global impression) 136 0.77b
Continent 57 (87.7%) 28 (82.4%) 29 (78.4%)
Improved 6 (9.2%) 3 (8.8%) 5 (13.5%)
Incontinent (failure) 2 (3.1%) 3 (8.8%) 3 (8.1%)
Micturition
Voiding pattern 136 0.71b
Normal 53 (81.5%) 30 (88.2%) 32 (86.5%)
Changedc 12 (18.5%) 4 (11.8%) 5 (13.5%)
PVR, ml 135 14.2±22.4 (0–100) 14.2±25.6 (0–120) 18.1±25.2 (0–120) 0.66a
Qmax, ml/s 111 20.4±8.1 (6.5–40.1) 23.5±9.0 (5.1–44.9) 20.6±6.9 (7.4–33.7) 0.26a
Midtape position, %d 135 53.8±6.7 (31.5–65.7) 52.5±8.1 (23.6–66.9) 50.6±10.8 (15.4–67.5) 0.55a
Data are expressed as mean±standard deviation and range (minimum–maximum), or number of patients (percent)
TVT tension-free vaginal tape, TOT outside-in transobturator tape Monarc, TVT-O inside-out transobturator tape TVT-O, PVR post-void residual
urine volume, Qmax maximum free-flow rate
a Kruskal–Wallis test
b Fisher’s exact test
c Any obstructive symptom like straining, requirement of postural changes in order to void, slow stream or hesitancy
d 0%=at meatus internus, 100%=at meatus externus
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different mesh properties may play a role. Indeed, the three
tapes consist of knitted polypropylene, and TOT has the
most similar mechanical behaviour to TVT or TVT-O [26].
There is a concern about presence of palpable tape,
particularly among the TO group, needing a longer-term
follow-up to determine whether this leads to extrusion [27].
Furthermore, TOT seems to give rise to more FSD than
TVT-O or TVT, probably as a result of vaginal narrowing
[28]. Incontinence surgery can affect sexual function. This
issue needs to be discussed in the informed consent.
Our study revealed a higher frequency of de novo FSD
in the TOT group. This is in contrast to anatomical studies
that compared TOT with TVT-O and presumed a lower
complication rate for outside-in TOT [29]. At initiation of
our study, we have not anticipated this issue, and only
recently, the importance of these complications is indepen-
dently and increasingly mentioned in the literature [19, 28].
In a 27-month follow-up of 233 women after TO tape
procedure, a de novo rate for dyspareunia of 9% was found
[19]. In our study, we found an FSD rate of 17% in the TOT
group. We decided to stop recruitment after having
observed this complication pattern about patients have to
be informed [9, 19].
Our study was undertaken in a teaching hospital setting,
involving several surgeons. Indeed, it is difficult to obtain
objective and clinical evidence in the daily clinical setup.
The strength of our study is its prospective randomised
design, comparing not only TVT with one TO technique,
but with the two TO techniques outside-in TOT and inside-
out TVT-O. The reason for the 2:1:1 relation was to achieve
an equal 1:1 distribution for TVT and TO techniques and
not to favour the TO techniques with a 1:1:1 distribution.
The weakness of our study was its design to detect a
difference in the voiding pattern by means of Qmax,
whereas for complication pattern a much higher number
of patients would be needed. In our study, we chose free-
flow rate to assess voiding function instead of a pressure-
flow study. This could be a limitation, although the
literature is quite controversial about this subject. In fact,
it was reported that free Qmax was significantly higher in
free uroflow studies than in pressure-flow studies, in both
obstructed and unobstructed patients [30]. Moreover,
comparison of detrusor pressure at maximum flow and
maximum detrusor pressure during voiding values did not
reveal significant differences, in both obstructed and
unobstructed patients. Due to the preterm stop of enrol-
Table 5 Tape-related complication pattern (n=160)
TVT TOT TVT-O Pa value
N randomised 80, n (%) 40, n (%) 40, n (%)
Intraoperative complications
Bladder perforation 3b (3.75) 0 (0) 0 (0) 0.43
Vaginal perforation 1 (1.25) 6 (15.0) 4 (10.0) 0.006
Postoperative complications
Haemorrhage 1c (1.25) 0 (0) 0 (0) 1.0
Postoperative interventions due to voiding obstructions
Early (tape loosening within the first week) 1 (1.25) 1 (2.5) 0 (0) 1.0
Late (tape release procedure within 12 months by complete
incision, including partial excision)
2d (2.5) 0 (0) 1e (2.5) 0.81
Second sling insertion 1c (1.25) 1 (2.5) 0 (0) 1.0
Short- and mid-term complications
Vaginal tape exposuref 1 (1.5) 4 (10) 0 (0) 0.028
Thigh or groin pain (not associated with sexual activity) 1 (1.5) 3 (8.3) 1 (2.7) 0.23
FSD (in sexually active patients; not associated with tape exposure) 1/52 (1.9) 5/29 (17.2) 0/25g (0) 0.011
Data are expressed as number of patients (percent)
TVT tension-free vaginal tape, TOT outside-in transobturator tape Monarc, TVT-O inside-out transobturator tape TVT-O, FSD female sexual
dysfunction
a Fisher’s exact test
bWhereof one conversion to TOT
c This patient needed a subsequent laparotomy. A second sling (TOT) was inserted at 6 months
d Due to one urinary retention and one de novo urge
e Due to urinary retention
f Erosion detected in one TVT at 4 weeks, in two TOT at 6 months, and in two TOT at 12 months
g Four TVT-O with preexisting FSD (and sexually active) are not included
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ment, our study is underpowered with 160 subjects,
reducing confidence in the primary endpoint outcomes.
A further weakness of the study was that we were only
partially able to follow the CONSORT guidelines. The ethic
committees requested a mandatory annual interim analysis, and
this may have led to an important information bias. Neverthe-
less, we believe that our study adds to the current knowledge
about sling operations and that this prospective randomised
controlled trial is useful in representing the daily clinical life.
Another weakness is the amount of missing data regarding
Qmax and QoL at 12 months. Eighteen percent of patients
could not void for the uroflow exam. In regard to QoL, up to
26% of the patients did not fill in the questionnaires. For the
domain “personal limitations”, missing data are even more
common due to missing partner or family.
Our study shows that it is important to follow-up patients
carefully, not only concerning defined endpoints, but also
concerning "new" side effects and symptoms that can
decrease QoL.
The patient complaint about FSD was very clear and
therefore clinically important. When we discussed the
yearly interim analysis, we realised the weakness of our
trial in this regard, namely that it was not designed for
detecting differences of this particular issue and that FSD
was no determined endpoint. We considered the higher
occurrence of FSD particularly in the TOT group clinically
important enough to stop our trial. This decision is
supported by the analysis of the corrected P value for
FSD. But due to the likelihood of bias caused by repeated
analyses and subgroup analyses, the results for FSD cannot
be generalised. Further prospective studies are needed using
a validated measure to evaluate FSD.
Our study adds to the growing evidence that TO tapes—
though equally effective in restoring continence—can, in
the mid- and long-term, impair patient’s satisfaction due to
complications like vaginal exposure or FSD [19, 28]. FSD
is a very important issue for any operation restoring quality
of life. Our data do not allow for generalisation. Therefore,
well-powered randomised controlled trials are needed to
answer this issue.
Women should be informed of these potential complica-
tions preoperatively and require careful follow-up after the
procedure. Further studies should focus on long-term
follow-up and the complication pattern particularly for the
current slings, as well as on a possible differential
indication, such as TVT for younger patients or for patients
with low-pressure urethra.
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